PRESS RELEASE published on 02/02/2026 at 08:00, 7 months 10 days ago CBI Announces the Launch of the emoji(TM) Marble Dash Playable Demo on the Epic Games Store Ahead of Its Token Community Sale CBI announces the launch of emoji™ Marble Dash demo on Epic Games Store, ahead of Token Community Sale starting on February 23, 2026, supported by Immutable ZKEVM blockchain CBI Epic Games Store Emoji Marble Dash Token Community Sale Immutable ZKEVM Blockchain
PRESS RELEASE published on 02/02/2026 at 08:00, 7 months 10 days ago Termination of a Liquidity Contract with BNP FINANCIAL MARKETS and Implementation of a New Liquidity Contract with Natixis ODDO BHF Vusion terminates liquidity contract with BNP FINANCIAL MARKETS, reveals resources in cash & shares, starts new contract with Natixis ODDO BHF. Company overview & commitment to sustainability Liquidity Contract NATIXIS ODDO BHF Sustainability Vusion Retail AI Solutions
PRESS RELEASE published on 02/02/2026 at 08:00, 7 months 10 days ago Cessation du contrat de liquidité contracté avec BNP Financial Markets et mise en oeuvre d'un contrat de liquidité avec Natixis ODDO BHF Vusion met fin au contrat de liquidité confié à BNP Financial Markets et met en place un nouveau contrat avec Natixis ODDO BHF pour ses actions cotées sur Euronext. Détails financiers et objectifs de l'entreprise NATIXIS ODDO BHF Liquidité Intelligence Artificielle Commerce Physique Vusion
PRESS RELEASE published on 02/02/2026 at 07:32, 7 months 10 days ago Mister Spex SE Confirms 2025 Guidance – consistent focus on profitability shapes business development Mister Spex SE confirms 2025 guidance with focus on profitability, achieving 18% net revenue decline. Disciplined approach shapes business development, emphasizing AOV growth and strategic decisions Profitability Mister Spex SE 2025 Guidance Net Revenue Decline AOV Growth
PRESS RELEASE published on 02/02/2026 at 07:30, 7 months 10 days ago Carvolix is born and funded French medtech company Affluent Medical rebrands as Carvolix after acquiring Caranx Medical and Artedrone. Completes 10m€ financing with Truffle Capital and Edwards Lifesciences for breakthrough AI-driven mini-robots and biomimetic implants in interventional cardiology and brain stroke treatment. Focus on expanding market and long-term value creation Affluent Medical Carvolix AI-driven Mini-robots Medtech Company Biomimetic Implants
PRESS RELEASE published on 02/02/2026 at 07:30, 7 months 10 days ago Carvolix : Résultats du vote de l’Assemblée Générale Mixte du 30 janvier 2026 Résultats du vote de l’Assemblée Générale Mixte de Carvolix du 30 janvier 2026. Approbation des résolutions et nominations. Détails des votes et taux de participation Résultats Assemblée Générale Mixte Vote Financières Carvolix
PRESS RELEASE published on 02/02/2026 at 07:30, 7 months 10 days ago Carvolix : Results of the votes of the Combined Shareholders’ General Meeting of January 30, 2026 Carvolix (formerly Affluent Medical) announces results of Combined Shareholders' Meeting, including name change approval and board member appointment Medical Technology Affluent Medical AI-driven Technology Combined Shareholders' Meeting Carvolix
PRESS RELEASE published on 02/02/2026 at 07:30, 7 months 10 days ago Carvolix est né et financé Affluent Medical devient officiellement CARVOLIX suite à l'acquisition de Caranx Medical et Artedrone pour révolutionner la cardiologie interventionnelle et les traitements des AVC avec des mini-robots IA et implants biomimétiques Acquisition Affluent Medical MedTech Carvolix Mini-robots IA
PRESS RELEASE published on 02/02/2026 at 07:30, 7 months 10 days ago Verve Group SE Announces Intention to Issue Subsequent Bonds to Capitalize on Business Momentum Following Strong Q4 Performance Verve Group SE intends to issue subsequent bonds following strong Q4 performance to capitalize on business momentum. The Company plans an aggregate total of €50 million Fixed Income Business Momentum Q4 Performance Subsequent Bonds Verve Group SE
PRESS RELEASE published on 02/02/2026 at 07:30, 7 months 10 days ago Affluent Medical officially becomes CARVOLIX Affluent Medical officially becomes CARVOLIX after completing the acquisitions of CARANX MEDICAL and ARTEDRONE, with a 10m€ first tranche of financing. Carvolix focuses on revolutionizing cardiac valve replacement and brain stroke treatment Innovation Acquisitions Financing Medical Technology Carvolix
Published on 09/12/2026 at 02:35, 17 hours 35 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 21 hours 10 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 22 hours 5 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 22 hours 45 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 3 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 2 hours 20 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 12 hours 39 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 21 hours 55 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 22 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 1 day 13 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 13 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ